Monitor ELEVIDYS sales recovery in 2026, especially with Japan launch and potential pathway back to serving non-ambulatory patients. Watch for updated guidance on profitability and cash flow sustainability. The strong pipeline data and financial restructuring provide long-term upside, but near-term execution on commercial recovery is key.
Price Chart
Executive Summary
Sarepta Therapeutics reported mixed financial results for 2025, with full-year revenue growing 16% to $2.20 billion driven by ELEVIDYS and collaboration revenue, but Q4 revenue declining 33% due to suspended shipments of ELEVIDYS to non-ambulatory patients. The company strengthened its financial position through debt refinancing and expects to remain profitable and cash-flow positive in 2026, while advancing its pipeline including positive three-year ELEVIDYS data and Japan launch.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue was $2.198 billion, up 16% YoY, driven by $77.9 million increase in ELEVIDYS net product revenue and $219.9 million in higher collaboration revenue
- Q4 2025 revenue was $442.9 million, down 33% YoY, primarily due to $273.8 million less in ELEVIDYS net product revenue after suspending shipments to non-ambulatory patients
- GAAP net loss was $713.4 million for 2025 vs. $235.2 million profit in 2024, with Q4 2025 GAAP net loss of $412.2 million vs. $159.0 million profit in Q4 2024
- Cash, cash equivalents, restricted cash and investments were $953.8 million as of December 31, 2025, down from $1.50 billion as of December 31, 2024
- Positive three-year EMBARK study data showed ELEVIDYS maintained motor function above baseline while control group declined, with 73% slowing of disease progression in Time to Rise and 70% in 10-meter walk/run
- ELEVIDYS launched in Japan in February 2026, with Sarepta eligible for a $40 million milestone payment upon first commercial sale
- Company refinanced $291.4 million of 2027 convertible notes into new 2030 notes plus $31.6 million cash, leaving only $158.6 million of original notes outstanding
Financial Impact
Revenue grew 16% to $2.20B for full year 2025 but declined 33% to $442.9M in Q4; net loss widened to $713.4M for 2025 from $235.2M profit in 2024
Segment Breakdown
| Segment | Revenue |
|---|---|
| PMO | $965.6M |
| ELEVIDYS | $898.7M |
Risk Factors
- Q4 revenue decline due to ELEVIDYS shipment suspension to non-ambulatory patients
- Widening net loss despite revenue growth, raising sustainability concerns
- Decline in cash position from $1.50B to $953.8M year-over-year
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-071566 |
| Document: srpt-20260225.htm | 0001193125-26-071566 |
| Document: 0001193125-26-071566-index-headers.html | 0001193125-26-071566 |
| Document: 0001193125-26-071566-index.html | 0001193125-26-071566 |
| Document: 0001193125-26-071566.txt | 0001193125-26-071566 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 27, 2026 9w ago | 8-K | $15.89 $18.13 | ▲ +14.10% | ▲ +10.80% | $17.50 (+10.13%) |
Jun 11, 2026 16w ago | Institutional Cluster | $15.00 $20.52 | ▲ +36.80% | ▲ +34.91% | $17.50 (+16.67%) |
Jun 4, 2026 17w ago | 8-K | $15.75 $19.18 | ▲ +21.78% | ▲ +19.92% | $17.50 (+11.11%) |
Apr 24, 2026 22w ago | DEFA14A | $20.89 $16.67 | ▼ −20.18% | ▼ −25.14% | $17.50 (−16.21%) |
Feb 25, 2026 31w ago | 8-K | $18.85 $23.75 | ▲ +26.00% | ▲ +31.24% | $17.50 (−7.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access